A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals?

This publication has 170 references indexed in Scilit:

• Glutamatergic Modulators for Major Depression from Theory to Clinical Use
  CNS Drugs, 2024
• Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression
  Psychopharmacology, 2021
• Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression
  JAMA Network Open, 2020
• Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression
  JAMA Psychiatry, 2019
• Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression
  JAMA Psychiatry, 2018
• Sex differences in brain‐derived neurotrophic factor signaling and functions
  Journal of Neuroscience Research, 2016
• The effects of low‐dose ketamine on the prefrontal cortex and amygdala in treatment‐resistant depression: A randomized controlled study
  Human Brain Mapping, 2016
• COGNITIVE DEFICITS AND FUNCTIONAL OUTCOMES IN MAJOR DEPRESSIVE DISORDER: DETERMINANTS, SUBSTRATES, AND TREATMENT INTERVENTIONS
  Depression and Anxiety, 2013
• A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression
  Archives of General Psychiatry, 2010
• A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
  Archives of General Psychiatry, 2006